Viagenpumatucel-L

Drug Profile

Viagenpumatucel-L

Alternative Names: Ad100-gp96Ig-HLA A1; Gp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell line; gp96-Ig lung cancer vaccine - Heat Biologics/University of Miami; HS-110; HS-L1

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator University of Miami
  • Developer Heat Biologics
  • Class Adjuvants; Cancer vaccines; Cell therapies; Heat shock proteins; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 31 Mar 2017 Heat Biologics has patents pending for cancer immunotherapies and vaccines in USA
  • 21 Mar 2017 Immunogenicity data from the phase Ib/II DURGA trial in Non-small cell lung cancer released by Heat Biologics
  • 13 Mar 2017 Additional efficacy data from the phase Ib/II DURGA trial in Non-small cell lung cancer released by Heat Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top